一个案例报告:在癌症患者中用 olanzapine 治疗失眠
Zhu Wang1, Kimberson Tanco2, Eric Liu3
1Section of Palliative Medicine, Division of General Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Palliative & supportive care
|June 20, 2025
概括
低剂量 olanzapine 在改善癌症患者的失眠方面表现有前途. 这种抗精神病药物也有助于减少恶心,吐和焦虑在某些情况下,保证进一步调查.
科学领域:
- 在瘤学瘤学.
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症患者经常患有失眠症,影响生活质量和治疗结果.
- 失眠会加剧现有的癌症症状,并可能阻碍康复.
- 有效的失眠管理对于癌症患者的福祉至关重要.
研究的目的:
- 评估低剂量 olanzapine 在治疗癌症患者失眠的疗效.
- 评估 olanzapine 对恶心,吐和焦虑等相关症状的影响.
- 为了探索 olanzapine 作为癌症相关失眠的非标签治疗的潜力.
主要方法:
- 约翰霍普金斯医院的医疗记录的回顾性审查.
- 包括3名癌症患者,他们患有不眠症,并接受了 olanzapine 治疗.
- 收集了有关癌症诊断,失眠严重程度和治疗结果的数据.
主要成果:
- 在所有3位研究的癌症患者中,olanzapine成功地改善了睡眠.
- 患者2和3经历了恶心/吐和焦虑的减少.
- 低剂量 olanzapine 证明对睡眠和相关症状有积极影响.
结论:
- 低剂量 olanzapine 在癌症患者的失眠中具有潜在的治疗选择.
- 需要进一步的研究,包括临床试验,以确定最佳剂量,长期风险和疗效.
- 瘤学提供者可能会考虑使用奥兰扎宾在癌症患者的非标签性失眠治疗.
相关概念视频
Management of Insomnia
328
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
328
Psychosis: Goals of Pharmacotherapy
214
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
214
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
461
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
461
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
330
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
330
Insomnia
132
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
132
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


